Xilio Therapeutics (XLO) Other Non-Current Liabilities (2020 - 2026)

Xilio Therapeutics has disclosed Other Non-Current Liabilities across 6 years of filings, most recently posting $30.2 million for Q2 2026.

• In Q2 2026, Other Non-Current Liabilities fell 21.66% year-over-year to $30.2 million; the TTM figure through Jun 2026 stood at $30.2 million (down 21.66% YoY), while the FY2025 annual figure was $29.6 million, changed N/A from the prior year.
• Other Non-Current Liabilities came in at $30.2 million for Q2 2026 at Xilio Therapeutics, up from $26.3 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $53.9 million in Q3 2025 to a low of $7000.0 in Q2 2023.
• Average Other Non-Current Liabilities over 4 years is $16.3 million, with a median of $100000.0 recorded in 2022.
• Year-over-year, Other Non-Current Liabilities plunged 95.8% in 2022 and dropped 21.66% in 2026.
• Over 4 years, Other Non-Current Liabilities stood at $45000.0 in 2022, then tumbled by 84.44% to $7000.0 in 2023, then surged by 422185.71% to $29.6 million in 2025, then advanced by 2.17% to $30.2 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Liabilities figures were $30.2 million in Q2 2026, $26.3 million in Q1 2026, and $29.6 million in Q4 2025.